Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Expanded access is currently available for this treatment.
Study NCT00704925 Information provided by University of California, Davis
First Received: June 23, 2008 No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lambert Eaton Myasthenic Syndrome
Additional conditions recognized in this trial
Lambert-Eaton Myasthenic Syndrome
Syndrome
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Disease
Immune System Diseases
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Neurodegenerative Diseases
Neuromuscular Diseases
Neuromuscular Junction Diseases
Paraneoplastic Syndromes
Paraneoplastic Syndromes, Nervous System
Pathologic Processes
Interventions listed in this trial
3, 4 DAP
Additional drug interventions recognized in this trial
3,4-diaminopyridine
More general drug interventions related to this trial
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Potassium Channel Blockers
Therapeutic Uses
Sponsors listed in this trial
University of California, Davis
Jacobus Pharmaceutical
Back to top of Main Content
